Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-31

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gastric cancer is the third major cancer of global cancer-related death. In China, the early diagnosis rate of gastric cancer is relatively low, and most patients are with locally advanced tumor stage. The neoadjuvant chemotherapy (NAC) can bring the survival advantage for gastric cancer patients with locally advanced tumor stage. The primary goal of NAC is to control the micrometastasis and/or progression of the primary lesion in order to improve potential of radical gastrectomy. NAC is recommended for patients with locally advanced stage (T2-4Nx) according to the latest NCCN Gastric Cancer Guidelines.

Laparoscopy distal gastrectomy (LDG) can achieve a better postoperative short-term recovery than the traditional open distal gastrectomy (ODG), which can reduce the intraoperative blood loss and to shorten the postoperative hospital stay. Therefore, Enhanced Recovery After Surgery program of gastric cancer surgery recommends the use of minimally invasive surgery. For long-term survival outcomes, there is limited evidence supported that laparoscopic gastrectomy is comparable open gastrectomy. Therefore, due to the lack of high-quality prospective clinical trial results, whether advanced tumor is suitable for laparoscopic surgery is still controversial. Therefore, some multi-center prospective randomized controlled trials have been carried out, compared safety and long-term survival outcome between laparoscopic and open gastrectomy in locally advanced gastric cancer patients. CLASS-01 trials reported that for locally advanced gastric cancers, laparoscopic D2 distal gastrectomy is safe and feasible.

Patient's surgical tolerance and stress response may be inhibited after the treatment of NAC. The aim of this trial is to confirm the safety of laparoscopy distal D2 radical gastrectomy for the treatment of after neoadjuvant chemotherapy gastric cancer patients (cT3-4a, N+, M0) in terms of postoperative complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer

NCT03273920

Gastric Cancer

UNKNOWN NA

Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

NCT05728606

Gastric Cancer

UNKNOWN NA

Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy

NCT06895447

Gastric Cancers

RECRUITING PHASE2

Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients

NCT02381847

Malignant Neoplasm of Stomach

UNKNOWN PHASE3

Robotic Total Gastrectomy for Locally Advanced Proximal Gastric Cancer

NCT03524287

Stomach Neoplasms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multi-centers, open-label, single-arm study, and the aim of this trial is to evaluate the safety of laparoscopic distal D2 radical gastrectomy for the treatment of locally advanced gastric cancer (cT3-4a, N-/+, M0) after neoadjuvant chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complications, Postoperative Surgery--Complications Cancer of Stomach Chemotherapy Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy

Group Type EXPERIMENTAL

Laparoscopic D2 distal gastrectomy

Intervention Type PROCEDURE

Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laparoscopic D2 distal gastrectomy

Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age from over 18 to under 75 years;
2. Primary gastric adenocarcinoma (including pap, tub, muc, sig, and por) confirmed pathologically by endoscopic biopsy;
3. cT3-4a, N-/+, M0 according to the AJCC 8th Cancer Staging Manual;
4. Without peritoneal metastasis (examined by laparoscopic examination);
5. Radical resection (R0) through distal subtotal gastrectomy with D2 lymphadenectomy is anticipated;
6. Performance status 0 or 1 (Eastern Cooperative Oncology Group) ;
7. ASA (American Society of Anesthesiology) score ≤ 3;
8. Normal hemodynamic indices:



1. Blood cell count: HB ≥ 90g/L, ANC ≥ 1.5×109/L, PLT ≥ 80×109/L;
2. Liver and renal function: BIL\<1.5 times of the upper limit of normal reference values, ALT and AST\<2.5 times of the upper limit of normal reference values, and Crea≤1 time of upper limits of normal reference values.

1. Therapeutic response rating after neoadjuvant chemotherapy is CR, PR, SD, or Therapeutic response rating after neoadjuvant chemotherapy is PD, tumor is expected to have radical resection;
2. Subjects are still willing to continue participating in this clinical trial.

Exclusion Criteria

1. History of upper abdominal surgery (include endoscopic mucosal resection or endoscopic submucosal dissection, except for laparoscopic cholecystectomy);
2. History of acute pancreatitis;
3. Enlarged or bulky regional lymph node (diameter\>3cm) by imaging exam;
4. Patients have received neoadjuvant therapy prior to screen work;
5. History of other malignant disease within the past five years;
6. History of cerebrovascular accident within the past six months;
7. History of continuous systematic administration of corticosteroids within the past month;
8. Scheduled simultaneous surgery for other disease;
9. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer;
10. Pyloric obstruction;
11. FEV1\<50% of predicted value;
12. Women who are pregnant or lactating at the time of screening;
13. Severe mental disorder;
14. Participating in other clinical studies;
15. Refused to sign the informed consent;

1. Therapeutic response rating after neoadjuvant chemotherapy is PD, involvement of adjacent structures(T4b), distal metastasis(M1), or enlarged or bulky regional lymph node (diameter\>3cm) by preoperative imaging
2. Patients cannot complete 3 cycles of chemotherapy due to intolerance;
3. After 3 cycles of neoadjuvant chemotherapy, patients cannot tolerate surgery due to severe adverse reactions, or ASA score ≥ 4 ;
4. Patients undertake emergency operation due to tumor bleeding, perforation or obstruction during chemotherapy;
5. After signing the informed consent, the patient withdraws from this clinical trial.

Withdrawal Criteria After Second Round:

1. Intro-abdominal metastasis of primary cancer is revealed intraoperatively;
2. Primary cancer is confirmed to be un-resectable intraoperatively.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jian-Kun Hu

Vice Director of Department of Gastrointestinal Surgery, West China Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jian-Kun Hu, M.D. Ph.D.

Role: PRINCIPAL_INVESTIGATOR

West China Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.